Prescription drug · NDA
Ery-Ped (erythromycin ethylsuccinate) NDC 24338-132
Erythromycin ethylsuccinate 200 mg/5mL · Suspension · Oral · Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 24338-132-13 | 24338013213 | 100 mL in 1 BOTTLE (24338-132-13)Marketed from Jul 5, 2011 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ery-Ped
- Generic name (nonproprietary)
- erythromycin ethylsuccinate
- Active ingredients
- Erythromycin ethylsuccinate — 200 mg/5mL
- Dosage form
- Suspension
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 050207
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Sebaceous Gland Activity (Physiologic effect)Macrolides (Chemical structure)
- Identifiers
- Product ID 24338-132_0ca6c02b-5b9f-39c3-e063-6294a90a4c18SPL ID 0ca6c02b-5b9f-39c3-e063-6294a90a4c18SPL set ID 04775721-ab87-4b66-808c-d67a21032385RxCUI 686400, 686402, 686418, 686420UNII 1014KSJ86F
- Pharmacologic class
- Macrolide Antimicrobial; Macrolide
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N424338013213followed by a unit qualifier and the quantityPackage 24338-0132-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respirato…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 050207
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Erythromycin Ethylsuccinate | Erythromycin ethylsuccinate 200 mg/5mL | Granule, For suspensionOral | Wilshire Pharmaceuticals Inc. | 52536-134 |
| Erythromycin Ethylsuccinate | Erythromycin ethylsuccinate 400 mg/5mL | SuspensionOral | Wilshire Pharmaceuticals | 52536-130 |
| Erythromycin Ethylsuccinate | Erythromycin ethylsuccinate 200 mg/5mL | SuspensionOral | Wilshire Pharmaceuticals | 52536-132 |
| Erythromycin Ethylsuccinate | Erythromycin ethylsuccinate 200 mg/5mL | Granule, For suspensionOral | Wilshire Pharmaceuticals Inc. | 52536-136 |
| Ery-Pederythromycin ethylsuccinate | Erythromycin ethylsuccinate 400 mg/5mL | SuspensionOral | Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) | 24338-130 |
| E.E.Serythromycin ethylsuccinate | Erythromycin ethylsuccinate 200 mg/5mL | Granule, For suspensionOral | Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) | 24338-134 |
| E.E.Serythromycin ethylsuccinate | Erythromycin ethylsuccinate 200 mg/5mL | Granule, For suspensionOral | Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) | 24338-136 |